Virological changes in chronic hepatitis type B treated with levamisole.
8 children, known to have been hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive for more than 6 months and with chronic active hepatitis on biopsy, received 2.5 mg levamisole/kg/day, 2 days a week for 6-18 months. In 6 of the 8 children transaminases normalized within 4-18 months of therapy, with seroconversion to antibody to HBeAg (anti-HBe) and disappearance of HBV-DNA polymerase from serum and of hepatitis B core antigen (HBcAg) from liver. In these cases liver biopsies taken after treatment showed histological regression to chronic persistent hepatitis. Two distinct patterns of response to levamisole were noted: patients having higher pretreatment transaminase levels and lower expression of HBcAg in the liver showed an early transaminase normalization and anti-HBe seroconversion with therapy, while in patients with less active disease and more diffuse HBcAg positivity in pretreatment liver biopsies, longer treatment periods were necessary to achieve these effects. Our results suggest that long-term levamisole therapy may be beneficial in HBeAg-positive chronic hepatitis type B.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004259:DNA-Directed DNA Polymerase / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D006512:Hepatitis B Core Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000235:genetics / Q000502:physiology; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D014779:Virus Replication / Q000187:drug effects
D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens; D007978:Levamisole; D004259:DNA-Directed DNA Polymerase